Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

Author(s):

Félix Guerrero-Ramos, MD, PhD, FEBU ,Srikala Sridhar, MD

Key Takeaways

CREST, POTOMAC, KEYNOTE, and ALBAN trials investigate PD-1/PD-L1 inhibitors for BCG-naive bladder cancer patients, focusing on efficacy and safety.
Routes of administration vary, with some trials using intravenous delivery and others exploring intravesical administration to optimize therapeutic outcomes.
Therapy durations differ among trials, with some opting for shorter treatment periods and others extending over several months to balance efficacy and safety.

Panelists discuss the specific PD-1/PD-L1 inhibitors currently being investigated in phase 3 trials for BCG-naive patients with non–muscle-invasive bladder cancer (NMIBC), including CREST, POTOMAC, KEYNOTE, and ALBAN, detailing how routes of administration and durations of therapy vary among these agents and emphasizing the significance of differences in control arms within the trials.

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

Now Viewing

EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP: 9.Exploring Emerging Data in NMIBC

EP: 10.Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

Can you explain in detail which PD-1/PD-L1 inhibitors are being investigated in phase 3 trials for BCG-naive patients? [describe CREST, POTOMAC, KEYNOTE, ALBAN,] (PMID 38849286; DOI 10.1016/S0302-2838(24)01302-2)
How do the routes of administration and durations of therapy differ among the agents/trials? Bedke 2023 Steinberg 2024